×
About 1,370 results

ALLMedicine™ Bleeding Time Center

Research & Reviews  441 results

The Antithrombotic Effect of Recombinant Neorudin on Thrombi.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169676
Drug Design, Development and Therapy; Liu YB, Zhang L et. al.

Jun 10th, 2022 - Recombinant neorudin (EPR-hirudin, EH) was developed through the addition of an EPR (Glu-Pro-Arg) peptide to the amino terminus of hirudin, which can be recognized and cut by coagulation factors XIa (FXIa) and/or Xa (FXa). In this study, the low-b...

Hematotoxicity of co-administration of bisphenol A and acetaminophen in rats and its am...
https://doi.org/10.2174/1871530322666220607124757
Endocrine, Metabolic & Immune Disorders Drug Targets; Akhter MS, Rashid H et. al.

Jun 9th, 2022 - Hematotoxicity is an underexplored end point of toxicity in most of the chemical exposures. An adverse effect on the hematological system arising out of xenobiotic exposure causes impaired hemostasis and coagulation leading to disease. BPA and ace...

Evaluation of the long-term results of vascular anastomosis using polyurethane adhesive...
https://doi.org/10.1002/micr.30926
Microsurgery Heitzer M, Ooms M et. al.

Jun 8th, 2022 - In free flaps, 5%-10% of complications are related to failure of sutured vascular anastomoses. Adhesive-based microvascular anastomoses are potential alternatives but are associated with failure rates of 70% in research studies. VIVO is a new adhe...

Conservative Treatment of PAS With or Without IIL
https://clinicaltrials.gov/ct2/show/NCT05232981

Jun 2nd, 2022 - This randomized control trial will be conducted at Tanta University hospital, Egypt, from 2022 to 2024. Tanta University Hospital is considered the main tertiary hospital at the center of Nile Delta . Cases, suspected to have PAS, are recruited fr...

see more →

Guidelines  1 results

Assessment of the risk of bleeding in patients undergoing surgery or invasive procedure...
https://doi.org/10.1016/j.thromres.2009.08.005
Thrombosis Research; Cosmi B, Alatri A et. al.

Sep 11th, 2009 - SYNOPSIS OF RECOMMENDATIONS: The Italian Society for Thrombosis and Haemostasis (SISET: Società Italiana per lo Studio dell' Emostasi e della Trombosi) promoted the development of a series of guidelines which would adopt evidence-based medicine me...

see more →

Drugs  35 results see all →

Clinicaltrials.gov  57 results

Conservative Treatment of PAS With or Without IIL
https://clinicaltrials.gov/ct2/show/NCT05232981

Jun 2nd, 2022 - This randomized control trial will be conducted at Tanta University hospital, Egypt, from 2022 to 2024. Tanta University Hospital is considered the main tertiary hospital at the center of Nile Delta . Cases, suspected to have PAS, are recruited fr...

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
https://clinicaltrials.gov/ct2/show/NCT04588727

May 20th, 2022 - The study will provide data on safety, tolerability, PK, and PD of AZD3366 in healthy subjects. Three populations (healthy subjects, healthy Japanese subjects and healthy Chinese subjects) will be enrolled into this study. This study will be condu...

Bilateral Erector Spina Block Versus Parasternal Block in Adult Heart Surgery
https://clinicaltrials.gov/ct2/show/NCT04090099

May 18th, 2022 - 99 patients will be included in the study. Group C (Control, n = 31), Group ES (Erector Spina, n = 31), Group PV (Paravertebral n = 31) will be randomized. A researcher will present the patient distribution to patients in a sealed envelope (1: 1: ...

CABG or PCI in Patients With Ischemic Cardiomyopathy
https://clinicaltrials.gov/ct2/show/NCT05329285

May 18th, 2022 - Short background/ Rationale/Aim: CABG has been shown to prolong survival in patients with reduced left ventricular (LV) function and multi-vessel coronary artery disease and "CABG is recommended as the first revascularization strategy choice in pat...

Ultrasound Guided Bilateral Erector Spinae Block Versus Caudal in Lumbar Spine Surgeries
https://clinicaltrials.gov/ct2/show/NCT05351203

May 10th, 2022 - This is a randomized controlled study designed to include 50 patients aged from 18 to 65 years old undergoing lumbar spine surgeries. fifty patients meeting the inclusion criteria will be randomly assigned into two equal groups: Group A(n=25): cau...

see more →

News  14 results

Novel Antiplatelet Agent May Not Increase Bleeding Risk
https://www.medscape.com/viewarticle/911977

Apr 18th, 2019 - A new approach to inhibiting platelets that may separate the antithrombotic effect from the bleeding risk has shown promising preliminary results, raising the hope of developing an agent for the treatment of acute ischemic stroke that can inhibit ...

Novel Antiplatelet Agent May Not Increase Bleeding Risk
https://www.staging.medscape.com/viewarticle/911977

Apr 18th, 2019 - A new approach to inhibiting platelets that may separate the antithrombotic effect from the bleeding risk has shown promising preliminary results, raising the hope of developing an agent for the treatment of acute ischemic stroke that can inhibit ...

Wisely Choosing the Right Lab Tests
https://www.medscape.com/viewarticle/888744

Dec 11th, 2017 - Hello and welcome. I am Dr George Lundberg, and this is At Large at Medscape. Most lab tests that are ordered do not need to be done. The results are either normal, negative, or show no change from the previous test. Why do them? I admit that ther...

Preventing thrombosis without increasing bleeding risk
https://www.mdedge.com/hematology-oncology/article/185637/thrombosis/preventing-thrombosis-without-increasing-bleeding-risk
HT Staff

Jun 1st, 2017 - Photo by Aaron Logan Lab mice It may be possible to disrupt thrombosis without increasing the risk of bleeding, according to preclinical research published in Nature Communications. “We have found a new thrombosis target that does not increase ble.

Antiplatelet agent may pose lower risk of bleeding
https://www.mdedge.com/hematology-oncology/article/186946/thrombosis/antiplatelet-agent-may-pose-lower-risk-bleeding
HT Staff

Jan 5th, 2017 - Cynomolgus macaque Photo by Sakurai Midori Researchers say they have developed an antiplatelet agent that has demonstrated considerable antithrombotic activity and low bleeding liability in monkeys. The agent, known as BMS-986120, is a PAR4 antago.

see more →